Optimization of Dosing Regimens for Plasminogen Activation Inhibitor BT-114143 Using a Small Molecule TMDD Population PK and PD Model in Healthy Subjects
European Journal of Drug Metabolism and Pharmacokinetics · 2026-03 · 51 (2) · 217-228
DOI: 10.1007/s13318-026-00987-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Drug Metabolism and Pharmacokinetics, online erschienen am 17.03.2026. Verfasst von Min Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: ScinnoHub Pharmaceutical Co., Ltd., Chengdu, Sichuan, 610059, People's Republic of China. Hauptthemen laut MEDLINE: Models, Biological, Antifibrinolytic Agents, Plasminogen. Die Arbeit nennt 35 Literaturangaben. Gefördert von: ScinnoHub Pharmaceutical Co., Ltd., Chengdu Brilliant Pharmaceutical Co., Ltd..
Abstract (Originalsprache)
BACKGROUND AND OBJECTIVE: BT-114143 is a novel, small-molecule antifibrinolytic agent that promotes hemostasis by inhibiting the conversion of plasminogen to plasmin. Due to its strong binding to this target, the drug exhibits target-mediated drug disposition (TMDD). This is characterized by nonlinear pharmacokinetics (PK) at low doses that transition to linearity at higher, target-saturating doses. In this study, a population pharmacokinetic-pharmacodynamic (PopPK-PD) model for BT-114143 was developed to guide dose selection for a subsequent multiple ascending dose (MAD) study. METHOD: Using PK and PD data from a single ascending dose (SAD) study of intravenously administered BT-114143, a PopPK-PD model was developed. RESULTS: The PopPK-PD analysis established that a TMDD PK model, combined with a sigmoid Emax PD model, adequately characterized the nonlinear PK and antifibrinolytic activity of intravenous BT-114143 in healthy subjects. The model identified the primary drivers of this TMDD behavior as the rapid binding of BT-114143 to plasminogen (association rate constant, Kₒₙ = 1.42 µM⁻1·h⁻1), its slow dissociation (dissociation rate constant, Koff = 0.0518 h⁻1), and the estimated total target concentration (Rₜₒₜ = 1.6 µmol/l). Furthermore, simulations predicted that twice-daily regimens of 2.4, 4.8, and 9.6 mg/kg would maintain steady-state trough concentrations (Ctrough) above the therapeutic threshold (≥ 2 µmol/l) throughout the dosing period. CONCLUSION: This study reports the first PopPK-PD model for a novel, plasminogen-targeting small-molecule exhibiting TMDD properties. The model was subsequently used to inform and support the design of multiple-dose regimens for future clinical studies in patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- ScinnoHub Pharmaceutical Co., Ltd., Chengdu, Sichuan, 610059, People's Republic of China.
- Center of Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, 410013, People's Republic of China.
- Chengdu Brilliant Pharmaceutical Co., Ltd., Chengdu, Sichuan, 610041, People's Republic of China.
- Center of Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, 410013, People's Republic of China. ygp9880@126.com.
- ScinnoHub Pharmaceutical Co., Ltd., Chengdu, Sichuan, 610059, People's Republic of China. jun.tang@scinnohub.com.
- Chengdu Brilliant Pharmaceutical Co., Ltd., Chengdu, Sichuan, 610041, People's Republic of China. jun.tang@scinnohub.com.
Förderung
- ScinnoHub Pharmaceutical Co., Ltd.
- Chengdu Brilliant Pharmaceutical Co., Ltd.
Zitieren
APA
Li, M., Li, Y., Zeng, S., Wang, Y., Ji, Y., Yang, G. P., & Tang, J. (2026). Optimization of Dosing Regimens for Plasminogen Activation Inhibitor BT-114143 Using a Small Molecule TMDD Population PK and PD Model in Healthy Subjects. European Journal of Drug Metabolism and Pharmacokinetics, 51(2), 217-228. https://doi.org/10.1007/s13318-026-00987-2
Vancouver
Li M, Li Y, Zeng S, Wang Y, Ji Y, Yang GP, et al. Optimization of Dosing Regimens for Plasminogen Activation Inhibitor BT-114143 Using a Small Molecule TMDD Population PK and PD Model in Healthy Subjects. European Journal of Drug Metabolism and Pharmacokinetics. 2026;51(2):217-228. doi:10.1007/s13318-026-00987-2
BibTeX
@article{Li2026,
author = {Li, Min and Li, Yafen and Zeng, Shaomei and Wang, Yaqi and Ji, Yafei and Yang, Guo-Ping and Tang, Jun},
title = {Optimization of Dosing Regimens for Plasminogen Activation Inhibitor BT-114143 Using a Small Molecule TMDD Population PK and PD Model in Healthy Subjects},
journal = {European Journal of Drug Metabolism and Pharmacokinetics},
year = {2026},
volume = {51},
number = {2},
pages = {217--228},
doi = {10.1007/s13318-026-00987-2}
}
EUVIMED